NEW YORK, NY / ACCESSWIRE / April 10, 2017 / The iShares NASDAQ Biotechnology Index ETF gained 0.80 percent to close at 290.52, up 9.47 percent year-to-date. Nektar Therapeutics and Clovis Oncology have recently seen a mixed bag of news for investors. Both companies are working on the development of cancer fighting drugs.

RDI Initiates Coverage on:

Nektar Therapeutics https://ub.rdinvesting.com/news/?ticker=NKTR

Clovis Oncology Inc. https://ub.rdinvesting.com/news/?ticker=CLVS

Nektar Therapeutics was down 4.42% to close at $20.11 on Friday. The stock traded between $19.65 and $21.07 on volume of 3.9mn shares traded. On April 4th, the company announced it had made 5 preclinical data presentations at the 2017 American Association for Cancer Annual Meeting. Its ongoing immune-oncology research with two primary candidate drugs, NKTR-214 and NKTR-255 has opened new possibilities for cancer treatment. Stephen Doberstein, Ph.D., Nektar's Senior Vice President and Chief Scientific Officer, said "These data showcase how Nektar's technology can be leveraged to target the IL-2 and IL-15 pathways in new ways in order to stimulate the body's immune system to fight cancer."

While the total revenue of Nectar declined marginally in the fourth quarter of 2016 to $37.5 million, compared to $39.4 million in the fourth quarter of 2015, its royalty revenue saw an increase to $6.4 million in the fourth quarter from $1.9 million a year ago.

Access RDI's Nektar Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=NKTR

Clovis Oncology declined 2.41% to close at $55.46 on Friday. The stock traded between $53.19 and $57.21 on volume of 3.2 million shares traded. The company appears to now have a competitor for its ovarian cancer drug, Rubraca, which received FDA approval last December. Current estimates place the sales of Rubraca optimistically at $462 million in 2018, allowing the company to have a positive cash flow as early as the beginning of 2018. The company recently presented rucaparib preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2017. Shares of Clovis Oncology have gained 24.85 percent year-to-date.

Access RDI's Clovis Oncology Research Report at: https://ub.rdinvesting.com/news/?ticker=CLVS

Our Actionable Research on Nektar Therapeutics (NASDAQ: NKTR) and Clovis Oncology Inc. (NASDAQ: CLVS) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com